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Valorization addendum 
158 
This thesis describes different dual target approaches to target hypoxic tumor-
associated carbonic anhydrase IX (CAIX). Firstly, the design, synthesis and biological 
evaluation of nitroimidazoles combined with carbonic anhydrase IX inhibitors 
(CAIXi), which showed the potential of increasing the efficacy of conventional 
treatment modalities such as chemo- and radiotherapy, has been described. Secondly, 
the development, synthesis and evaluation of anti-cancer drugs in combination with 
CAIXi derivatives, targeting the hypoxic tumor microenvironment to decrease normal 
tissue toxicity, have been demonstrated. Lastly, the design, synthesis and evaluation 
of biological efficacy of bio-reducible drugs, which undergo a reduction under 
hypoxic conditions, incorporating a CAIXi moiety have been described. However, 
developing new anti-cancer drugs remains challenging, since cancer is an extremely 
heterogeneous disease consisting of distorted versions of a person’s own cells. 
Moreover increasing cancer incidence has a severe socio-economic impact and the 
development of new anti-cancer drugs remains essential. This valorization addendum 
discusses CAIX targeting using different approaches, its value for the gain for general 
society and future of cancer treatment. 
Clinical Relevance 
Since the treatment of cancer patients is progressing into a personalized treatment, the 
knowledge about the hypoxic tumor microenvironment and heterogeneity plays an 
important role. Conventional therapies such as chemo- and radiotherapy are less 
effective towards hypoxic tumors and therefore patient prognosis is worse. Many 
biomarkers have been already identified to stratify patients for a personalized 
treatment. CAIX is a transmembrane enzyme, its overexpression is highly tumor-
specific especially under hypoxic conditions and generally associated with worse 
prognosis for cancer patients. Therefore, CAIX might be considered as a valuable 
biomarker for stratification of cancer patients, although the specific treatment based 
on this type of stratification remains to be identified. Since CAIX expression under 
hypoxic conditions is highly cell line dependent, targeted CAIX imaging may not be a 
universal hypoxia imaging strategy, and therefore, would be of limited use for clinical 
practice. CAIX catalyzes the reversible hydration of carbon dioxide to bicarbonate 
and a proton, a chemical reaction implicated in several carcinogenic processes such as 
invasion and migration. The clinical benefits of using CAIX inhibitors in patients 
however remain to be investigated. The dual target compounds to target CAIX with 
different approaches described in this thesis (Chapter 3, 4, 5, 6) will unlikely be 
implemented in clinical practice due to limited efficacy. So far, there is only one 
CAIX inhibitor (i.e. SLC-0111) in clinical trials. The phase I clinical trial 
(NCT02215850) has been successfully finished end 2016. Currently the compound is 
scheduled to enter phase II trials this year.  
Gain for Society 
The Transmembrane location and the tumor-specific overexpression of CAIX can 
facilitate multiple targeting strategies. Firstly, since hypoxic tumors show resistance 
to conventional therapies such as chemo- and radiotherapy, a dual targeting approach 
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with radiosentizers targeting CAIX can increase the efficacy of standard treatment 
modalities. Secondly, treatment costs will decrease when healthy tissue side effects 
caused by anti-cancer therapy can be reduced, e.g. specific delivery of cytotoxic drugs 
to tumor site via targeting CAIX. Lastly, hypoxia activated prodrugs or bio-reducible 
drugs, which are activated and become cytotoxic under hypoxia, can also decrease 
side effects by killing specifically the hypoxic tumor cells. In general, any of these 
advancement in treatment of cancer has a potential gain for society. 
 
Improvement in Health Care 
CAIX expression in normal human tissues is rare, except in GI tract and this 
expression either decreased or lost during carcinogenesis. This atypical expression 
helps as biomarker for theragnostic purposes, inhibiting CAIX alone with inhibitors 
may not be enough to improve the health care. During the last decade, a large variety 
of CAIX inhibitors, several reported in this thesis, have been developed, but definitive 
conclusions regarding the efficacy of a single CAIX inhibitor treatment can only be 
drawn after completing clinical trials. Dual drug targeting approaches to increase the 
efficacy of conventional treatment modalities, sparing normal tissues by specific drug 
delivery to the tumor site and bio-reducible drugs that become cytotoxic only under 
hypoxic conditions are expected to improve health care as patients will experience 
less toxic side effects but required additional interventions (Chapter 3, 4, 5, 6). These 
approaches can potentially increase the therapeutic window of anti-cancer therapy and 
thereby result in an improvement in health care.  
In addition, CAIX expression is tumor-specific and has prognostic value in a wide 
variety of cancers types. The expression levels of CAIX could therefore serves as 
excellent biomarker for patient selection, although the relevant therapies remain to be 
identified. CAIX might also be a diagnostic tool for early detection of malignant 
lesions, e.g. implementing CAIX imaging can lead to a great improvement in health 
care, since early detection of cancer can increase the patient’s chance of survival. 
 
Novelty of the Concept 
Targeting CAIX with different inhibitors is not novel, but recently different 
approaches of dual drug targeting, as discussed in this thesis, gained a lot of interest 
by researchers. CAIX is a potential therapeutic target due to its tumor-specific 
expression and its involvement in maintaining a pH balance between the acidic 
extracellular and the alkaline intracellular environment of tumor cell. The acidic 
extracellular tumor microenvironment promotes several carcinogenic processes such 
as migration and invasion. By reducing this extracellular acidification via inhibiting 
CAIX activity using nitroimidazoles incorporated with CAIXi, the efficacy of 
conventional treatment modalities might increase (Chapter 3). The interaction 
between CAIXi and conventional treatment modalities needs to be understood very 
well before entering into clinical trials.  
Although cytotoxic drugs targeting CAIX have been described previously, these 
approaches were studied predominantly in renal cell carcinoma where CAIX 
expression is upregulated due to a mutation in the VHL protein preventing HIF-1α 
degradation. This thesis described a novel method of delivering anti-cancer drugs 
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towards CAIX expressing cells via dual target compounds (Chapter 4), which 
conjugated with CAIXi. However, these dual target compounds showed little 
preference for CAIX expressing cells, which minimized their practical applicability. 
Further exploration on pharmacokinetic studies on these dual target drugs may help to 
design more potent approaches to deliver cytotoxic drugs towards CAIX expressing 
cells. This thesis describes a novel approach of bio-reducible cytotoxic warheads 
conjugated with CAIXi. Most of the bio-reducible drugs described in Chapter 5 did 
not show strong binding affinity towards physiologically relevant CA isoforms, this 
might be explained by the influence of the linker and substitution on aromatic ring. 
Chapter 6 described 2-, 5-nitroimidazole and nitrogen mustard sulfonamides based 
derivatives. Interestingly, a cell dependent cytotoxicity has been observed for the 2-
nitroimidazole-based compounds, an effect explained by the higher reduction 
potential of 2-nitroimidazoles compared to 5-nitroimidazoles. 2-nitroimidazole bio-
reducible drugs may serve as less toxic drugs towards normal tissues surrounding the 
tumor and further combination with radiation might increase therapeutic efficacy. 
Structure Activity Relationship studies on bio-reducible drugs conjugated with CAIXi 
might help to develop new anti-cancer drugs. 
 
Road to the Market 
CAIX is an interesting anti-cancer therapeutic target and the tumoral expression of 
CAIX may be promising for the future market. The research described in this thesis 
does have potential clinical relevance that could eventually lead to an improved health 
care. However, additional in vivo preclinical and clinical experiments remain 
essential. The prognostic value, tumor-specific expression and surface location of 
CAIX facilitate it to be a potential biomarker. For this purpose, investigations on the 
outcome and progression of CAIX-positive hypoxic cancer versus CAIX-negative 
hypoxic cancer should be conducted. Immunohistochemical evaluation of CAIX 
expression requires a specific antibody to detect CAIX, currently the M75 antibody 
available in the market. However, the development of a fast and easy to use kit to 
evaluate CAIX expression might therefore more promising, which is currently 
unavailable. Many CAIX directed antibody-drug conjugated candidates were 
reported, but there is not yet an approved therapeutic drug targeting this antigen.  
The CAIX inhibitors described in Chapter 3 however will not be pursued further as 
they were either ineffective as single agents, or unable to increase the efficacy of 
conventional treatment modalities. However, the single agent CAIX inhibitor i.e. 
SLC-0111 entered into phase II clinical trials and future clinical trials should also 
investigate the effect of SLC-0111 on the efficacy of conventional treatment 
modalities. 
Monitoring of CAIX expression levels can be used to stratify patients for a specific 
therapy that has been proven to be effective for e.g. specific cytotoxic drug delivery to 
tumor site by targeting CAIX. Another approach is the use of bio-reductive drugs 
conjugated with CAIXi that might improve the drug uptake by tumors expressing 
CAIX with minimal side effects. In future, this approach might help the development 
of new anti-cancer drugs targeting CAIX with a potentially clinical relevance. 
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Overall this thesis described several dual target approaches to target CAIX, but the 
most promising approach to utilize CAIX as target are the targeted drug delivery of 
cytotoxic compounds and bio-reductive cytotoxic drugs conjugated with CAIXi. In 
addition, the identification of alternative approaches to target CAIX remain essential, 
but requires further preclinical and clinical research in order to assess CAIX as a 
therapeutic target and its influence on healthcare and gain for society.   
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
